Literature DB >> 33194498

Clinical Rhabdomyolysis With Acute Kidney Injury Secondary to High-Intensity Rosuvastatin Use: A Case Report.

Deepak Chitralli1, Ronak Raheja2, Kishore Br2.   

Abstract

Statins are the primary class of medication used to lower serum cholesterol concentration for both primary and secondary prevention of cardiovascular disease. Muscle pain is a frequent adverse effect of statins. Severe myonecrosis leading to clinical rhabdomyolysis is rare. We encountered a 63-year-old male with a medical history of hypertension, type 2 diabetes mellitus, and coronary artery disease with angioplasty in 2008 and 2020. He was started on rosuvastatin 40 mg (0-0-1) along with dual anti-platelets post angioplasty and was discharged home. He traveled back to his hometown and noticed progressive symmetric muscle weakness with decreased urine output. After visiting another hospital he presented to us with severe proximal muscle weakness and acute renal failure. Laboratory investigations were initiated which demonstrated clinically significant derangement in serum creatinine phosphokinase, serum creatinine, urine myoglobin along with deranged liver enzymes. He was subjected to nerve conduction studies for his muscle weakness which was normal and electromyography showed abnormal spontaneous muscle activity in all examined muscles (fibrillations, positive sharp waves, and pseudomyotonic discharges) suggestive of an irritable myopathy. The medication was stopped and he was treated with eight cycles of hemodialysis until his muscle weakness and laboratory parameters improved. He was then discharged with some improvement in muscle weakness. On two week follow-up, the patient showed partial improvement after discontinuation of all lipid-lowering medication.
Copyright © 2020, Chitralli et al.

Entities:  

Keywords:  intensity of statin dosing; myoglobin; myopathy; proximal myopathy; statin-induced necrotizing autoimmune myopathy

Year:  2020        PMID: 33194498      PMCID: PMC7660123          DOI: 10.7759/cureus.10932

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  8 in total

1.  Can statins cause chronic low-grade myopathy?

Authors:  Scott M Grundy
Journal:  Ann Intern Med       Date:  2002-10-01       Impact factor: 25.391

Review 2.  Primary Prevention With Statins in the Elderly.

Authors:  Martin Bødtker Mortensen; Erling Falk
Journal:  J Am Coll Cardiol       Date:  2018-01-02       Impact factor: 24.094

3.  NLA Task Force on Statin Safety--2014 update.

Authors:  Terry A Jacobson
Journal:  J Clin Lipidol       Date:  2014 May-Jun       Impact factor: 4.766

Review 4.  Risks associated with statin therapy: a systematic overview of randomized clinical trials.

Authors:  Amir Kashani; Christopher O Phillips; JoAnne M Foody; Yongfei Wang; Sandeep Mangalmurti; Dennis T Ko; Harlan M Krumholz
Journal:  Circulation       Date:  2006-12-11       Impact factor: 29.690

5.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Authors:  David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

6.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson
Journal:  J Am Coll Cardiol       Date:  2013-11-12       Impact factor: 24.094

7.  Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; David C Goff; Donald M Lloyd-Jones; Sidney C Smith; Conrad Blum; J Sanford Schwartz
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

8.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

  8 in total
  1 in total

1.  Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria.

Authors:  Jung-Im Shin; Derek M Fine; Yingying Sang; Aditya Surapaneni; Stephan C Dunning; Lesley A Inker; Thomas D Nolin; Alex R Chang; Morgan E Grams
Journal:  J Am Soc Nephrol       Date:  2022-07-19       Impact factor: 14.978

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.